Aurinia Pharmaceuticals Inc (AUPH) concluded trading on Wednesday at a closing price of $5.74, with 5.58 million shares of worth about $32.02 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -39.90% during that period and on Wednesday the price saw a gain of about 2.68%. Currently the company’s common shares owned by public are about 143.83M shares, out of which, 131.48M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 44 times over the past 12 months. They bought 2,204,613 shares in 35 of the transactions. In 9 selling transactions, insiders dumped 6,417,799 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of -26.22% in past 5 days and over the past one month there was a price change of -29.14%. Year-to-date (YTD), AUPH shares are showing a performance of -36.15% which decreased to -29.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.50 but also hit the highest price of $12.43 during that period. The average intraday trading volume for Aurinia Pharmaceuticals Inc shares is 2.52 million. The stock is currently trading -24.31% below its 20-day simple moving average (SMA20), while that difference is down -30.45% for SMA50 and it goes to -36.49% lower than SMA200.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) currently have 143.83M outstanding shares and institutions hold larger chunk of about 36.52% of that.
The stock has a current market capitalization of $830.12M and its 3Y-monthly beta is at 1.43. It has posted earnings per share of -$0.55 in the same period. It has Quick Ratio of 4.99 while making debt-to-equity ratio of 0.26. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUPH, volatility over the week remained 7.85% while standing at 4.90% over the month.
Analysts are in expectations that Aurinia Pharmaceuticals Inc (AUPH) stock would likely to be making an EPS of -$0.11 in the current quarter, while forecast for next quarter EPS is -$0.02 and it is $0.4 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.2 which is $0.01 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.18 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 96.76% while it is estimated to increase by 2252.38% in next year.
Coverage by Cantor Fitzgerald stated Aurinia Pharmaceuticals Inc (AUPH) stock as an Overweight in their note to investors on May 05, 2022, suggesting a price target of $25 for the stock. On December 10, 2021, Oppenheimer Upgrade their recommendations, while on October 28, 2021, Oppenheimer Downgrade their ratings for the stock with a price target of $32. Stock get a Buy rating from H.C. Wainwright on January 25, 2021.
